Ionis Pharmaceuticals, Inc. (LON:0JDI)
Market Cap | 8.70B |
Revenue (ttm) | 689.06M |
Net Income (ttm) | -195.77M |
Shares Out | n/a |
EPS (ttm) | -1.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 351 |
Average Volume | 664 |
Open | 72.69 |
Previous Close | 72.50 |
Day's Range | 72.45 - 73.68 |
52-Week Range | 24.11 - 74.20 |
Beta | n/a |
RSI | 78.43 |
Earnings Date | Nov 5, 2025 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE... [Read more]
Financial Performance
In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.
Financial numbers in USD Financial StatementsNews
Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharmaceuticals Inc (IONS)
Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharmaceuticals Inc (IONS)
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News

Ionis to hold third quarter 2025 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its thir...
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call - Slideshow
2025-10-08. The following slide deck was published by Ionis Pharmaceuticals, Inc.
Needham Raises Price Target on Ionis Pharmaceuticals (IONS) to $78 | IONS Stock News
Needham Raises Price Target on Ionis Pharmaceuticals (IONS) to $78 | IONS Stock News
Oppenheimer Raises Ionis Pharmaceuticals (IONS) Price Target to $90 | IONS Stock News
Oppenheimer Raises Ionis Pharmaceuticals (IONS) Price Target to $90 | IONS Stock News
JP Morgan Boosts Ionis Pharmaceuticals (IONS) with Upgrade and Price Target Increase
JP Morgan Boosts Ionis Pharmaceuticals (IONS) with Upgrade and Price Target Increase

Ionis upgraded at JP Morgan on expanding Tryngolza market, pipeline
JP Morgan upgrades Ionis Pharmaceuticals to overweight, citing Tryngolza expansion and strong pipeline. Read more here.
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
Ionis Pharmaceuticals guided to north of $5 billion in peak sales. Early Wednesday, Ionis stock was approaching a six-year high.
JP Morgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight, Raises Price Target | IONS Stock News
JP Morgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight, Raises Price Target | IONS Stock News

JPMorgan upgrades biopharma stock to overweight on strong drug pipeline
JPMorgan foresees shares of Ionis Pharmaceuticals rising another 16% from their Tuesday close after a 170% runup in six months.
HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (IONS) | IONS Stock News
HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (IONS) | IONS Stock News
Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript
Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on
Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more

Watch CNBC's full interview with Ionis Pharmaceuticals CEO Brett Monia
Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on
Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term...
Ionis Pharmaceuticals (IONS): Stifel Raises Price Target to $67 | IONS Stock News
Ionis Pharmaceuticals (IONS): Stifel Raises Price Target to $67 | IONS Stock News
Insider Sell Alert: Patrick O'neil Sells 64,664 Shares of Ionis Pharmaceuticals Inc (IONS)
Insider Sell Alert: Patrick O'neil Sells 64,664 Shares of Ionis Pharmaceuticals Inc (IONS)
Insider Sell: Patrick O'neil Sells 25,300 Shares of Ionis Pharmaceuticals Inc (IONS)
Insider Sell: Patrick O'neil Sells 25,300 Shares of Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc (Symbol: IONS) was identified as having a larger market cap than the smaller end...
Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News
Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News
Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News
Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News
Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target Price Increase | IONS Stock News
Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target Price Increase | IONS Stock News